Expanded Program On Immunization

Expanded Program on Immunization

Background and Definition

Expanded Program on Immunization (EPI), established in 1987, aimes at guaranteeing the right of every child in Lebanon, regardless of social status or parent's education level, on immunization and protection from diseases that have available effective and safe vaccines. In order to ensure that, the Ministry of Public Health guarantees the provision of vaccines in 700 health care centers, public and social, in collaboration with the private sector and with the conitnuous awareness of care givers about the importance of immunization. The program provides further special attention to chidlren residing in remote and underprivileged areas through quality outreach activities.

EPI ِAims at:

Elevating routine vaccination coverage per district to above 95%.
Preserving Lebanon as polio-free, considering the continuous influx of Syrian refugees and in preparation to the eradication of polio in the region and worldwide.
Eradicating Measles and Rubella by the end of year 2018.

EPI Activities:

Continuous training and capacity building throughout the year for health care workers on routine vaccination management and implementation in all districs.
Continuous work to keep Lebanon certified polio-free
Implementation of the RED STRATEGY to reach every child, which includes:
1. Data on the immunization coverage for children under one year of age
2. Data on immunization coverage in Lebanon
3. Identification of the number of drop-outs and planning to ensure their vaccination per district accordingly
Celebrating World Immunization Week and planning awareness sessions over Lebanon about routine vaccination
Conducting National and Mop-Up Immunization campaigns annually, including vaccination against Measles, Rubella, and Mumps
Conducting regular visits by the self-assessment team to follow on the quality of vaccination delivery service
Continuous collaboration with UNICEFand WHO to follow-up on updates related to immunization worldwide and ensuring implementation in Lebanon considering national and international commitments
Continuous collaboration with the private sector (General Practictioners and Pediatricians) to ensure vaccination for all children in Lebanon, particularly during immunization campaigns and routine immunization.

...

All

ATC	Name	B/G	Ingredients	Dosage	Form	Price
M01AC02	SORAL	G	Tenoxicam - 20mg/2ml	20mg/2ml	Injectable lyophilised powder for solution+solvent	588,603 L.L
J01DH51	SYNERGIC	G	Imipenem - 500mg, Cilastatin - 500mg		Injectable powder	1,142,266 L.L
L04AC02	SIMULECT	BioTech	Basiliximab - 20mg	20mg	Injectable powder + solvent	137,661,787 L.L
L01XX02	SPECTRILA	BioTech	Asparaginase, recombinant - 10,000IU	10,000IU	Injectable powder for concentrate for solution	21,370,813 L.L
A02BC05	SOLEZOL	G	Esomeprazole - 40mg	40mg	Injectable powder for solution	301,021 L.L
H02AB04	SOLU MEDROL	B	Methylprednisolone sodium succinate - 500mg	500mg	Injectable powder for solution	718,956 L.L
H02AB04	SOLU MEDROL	B	Methylprednisolone sodium succinate - 1g	1g	Injectable powder for solution	1,444,631 L.L
J01DE01	SALAPIME	G	Cefepime - 1g	1g	Injectable powder for solution	618,168 L.L
H02AB04	SOLU MEDROL Act-O-Vial	B	Methylprednisolone sodium succinate - 40mg	40mg	Injectable powder for solution+diluent	318,491 L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 20mg	20mg	Injectable powder for suspension+diluent	L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 30mg	30mg	Injectable powder for suspension+diluent	L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 20mg	20mg	Injectable powder for suspension+diluent	38,121,223 L.L
H01CB02	SANDOSTATIN LAR	B	Octreotide (acetate) - 30mg	30mg	Injectable powder for suspension+diluent	57,182,544 L.L
M05BA08	SIMPLA	G	Zoledronic acid - 5mg/100ml	5mg/100ml	Injectable solution	13,071,402 L.L
P01AB01	SOLUFLEX METRONIDAZOLE	G	Metronidazole - 500mg/100ml	500mg/100ml	Injectable solution	162,541 L.L
N01AH03	SUFENTANIL RENAUDIN	G	Sufentanil (citrate) - 250mcg/5ml	250mcg/5ml	Injectable solution	3,524,899 L.L
N01AH03	SUFENTANIL RENAUDIN	G	Sufentanil (citrate) - 5mcg/ml	10mcg/2ml	Injectable solution	755,239 L.L
A10BJ02	SAXENDA	BioTech	Liraglutide - 6mg/ml	6mg/ml	Injectable solution	16,747,035 L.L
A10BJ06	SEMATIDE	G	Semaglutide - 1mg	1mg	Injectable solution	9,288,397 L.L
A10BJ06	SEMATIDE	G	Semaglutide - 0.25mg & 0.5mg		Injectable solution	9,288,397 L.L
N01BB03	SCANDONEST 3% sans vasoconstricteur	B	Mepivacaine - 54mg/1.8ml	3%	Injectable solution	1,670,396 L.L
N01BB03	SCANDINIBSA	G	Mepivacaine HCl - 3%	3%	Injectable solution	1,191,988 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
J06BD01	SYNAGIS	BioTech	Palivizumab - 100mg/ml	100mg/ml	Injectable solution	57,429,464 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	158,587 L.L
J06BD01	SYNAGIS	BioTech	Palivizumab - 50mg/0.5ml	50mg/0.5ml	Injectable solution	38,316,693 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	171,228 L.L
B05CX01	SERUFLEX DEXTROSE 5% INJECTION, USP	G	Glucose - 5%	5%	Injectable solution	193,062 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L
B05CX01	SOLUFLEX DEXTROSE 5% INJECTION USP	G	Glucose - 5%	5%	Injectable solution	186,167 L.L

...